Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6976893 | 0.79 | CA12 (0.42) | MMP2MMP3MMP13CYP1A2CYP2C19 | |
| SCHEMBL4948092 | 0.78 | PSMD10 (0.42) | CTSGCMA1EGFRERBB2LMNA | |
| SCHEMBL6880345 | 0.78 | MMP3 (0.45) | MMP2MMP3MMP13STAT3CA12 | |
| SCHEMBL4580222 | 0.77 | SLC7A5 (0.46) | CTSGCMA1EGFRSLC7A5MAPT | |
| SCHEMBL18591888 | 0.77 | CYP2D6 (0.47) | SLC7A5MAPT | |
| SCHEMBL9672034 | 0.77 | CA12 (0.47) | LMNAMMP2MMP3MMP13CYP3A4 | |
| SCHEMBL290277 | 0.74 | SLC7A5 (0.48) | CTSGCMA1EGFRSLC7A5PKM | |
| SCHEMBL18530362 | 0.73 | SLC7A5 (0.41) | CTSGCMA1SLC7A5CYP1A2CYP3A4 | |
| SCHEMBL26814033 | 0.73 | LMNA (0.38) | LMNAPKMCA1CA2L3MBTL1 | |
| SCHEMBL4951364 | 0.73 | SLC7A5 (0.39) | SLC7A5PKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11554171-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | ARVINAS OPERATIONS, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| US-20210187108-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10772962-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | ARVINAS OPERATIONS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| EP-3337476-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2017-03-09 | — | — | US | disclosed |
| WO-2017030814-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017030814-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772962-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | BRPF3, STUB1, BRDT | CTSG 2123/4885CMA1 1718/4885EGFR 1010/4885 |
| US-11554171-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | BRPF3, STUB1, BRDT | CTSG 2123/4885CMA1 1718/4885EGFR 1010/4885 |
| US-20210187108-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | CTSG 2123/4885CMA1 1718/4885EGFR 1010/4885 |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | CTSG 2123/4885CMA1 1718/4885EGFR 1010/4885 |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | CTSG 2123/4885CMA1 1718/4885EGFR 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.